Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine plus nab-paclitaxel (NabG).

被引：4
|
作者：
Schmidt, Shannon Leah
Durkal, Vipal
Jayavalsan, Shinoj Pattali
Thomas, James P.
Ritch, Paul S.
Erickson, Beth
Christians, Kathleen K.
Tsai, Susan
Evans, Douglas B.
George, Ben
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Froedtert Hosp, Milwaukee, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.397
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
397
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Treatment outcomes with first-line (1L) nab-Paclitaxel plus gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma (mPAC).
    Cartwright, Thomas H.
    Parisi, Monika
    Espirito, Janet L.
    Wilson, Thomas
    Pelletier, Corey
    Patel, Manish
    Babiker, Hani M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [3] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Han, Sung Yong
    Kim, Dong Uk
    Seol, Young Mi
    Kim, Suk
    Lee, Nam Kyung
    Hong, Seung Baek
    Seo, Hyung-Il
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (17) : 3718 - 3729
  • [4] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Sung Yong Han
    Dong Uk Kim
    Young Mi Seol
    Suk Kim
    Nam Kyung Lee
    Seung Baek Hong
    Hyung-Il Seo
    World Journal of Clinical Cases, 2020, (17) : 3718 - 3729
  • [5] Modified FOLFIRINOX for metastatic pancreatic adenocarcinoma after failure of nab-paclitaxel plus gemcitabine.
    Ozaka, Masato
    Sasaki, Takashi
    Kataoka, Seita
    Kanata, Ryo
    Ishigaki, Kazunaga
    Yamada, Ikuhiro
    Matsuyama, Masato
    Takano, Koichi
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [6] Real world hospital costs associated with nab-paclitaxel plus gemcitabine (nab-P plus G) and FOLFIRINOX (FFX) as first line (1 L) treatment (tx) for metastatic pancreatic adenocarcinoma (MPAC).
    Kim, George P.
    Parisi, Monika
    Patel, Manish
    Belk, Kathy
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Survival outcomes based on sequence of therapy using FOLFIRINOX and nab-paclitaxel plus gemcitabine in metastatic pancreatic ductal adenocarcinoma
    Baron, Kelsey
    Nevala-Plagemann, Christopher Duane
    Moser, Justin
    Haaland, Benjamin
    Wang, Xuechen
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel plus Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma
    Baron, Margaret Kelsey
    Wang, Xuechen
    Nevala-Plagemann, Christopher
    Moser, Justin C.
    Haaland, Benjamin
    Garrido-Laguna, Ignacio
    PANCREAS, 2021, 50 (06) : 796 - 802
  • [9] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
    Ozaka, Masato
    Sasaki, Takashi
    Yamada, Ikuhiro
    Kanata, Ryo
    Akiyama, Dai
    Katagiri, Tomoko
    Takano, Koichi
    Matsuyama, Masato
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [10] Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
    Yamamura, T.
    Nakano, S.
    Saito, R.
    Ito, K.
    Nakatsumi, H.
    Harada, K.
    Kawamoto, Y.
    Yuki, S.
    Sakamoto, N.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1312 - S1312
12345